REDONDO BEACH, CA–(Marketwired – Apr 12, 2017) –  SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing AXIM® Biotechnologies Inc.’s (OTCQB: AXIM) progress in ophthalmology.

Medical cannabis has gained widespread acceptance for several different medical indications, but ophthalmology isn’t one of them – with many members of the community recommending against the use of the drug. While research in the 1970s may have been inconclusive, new research suggests that the interaction of multiple cannabinoids could play a multi-factor role in reducing intraocular pressure (“IOP”) and inflammatory conditions in the back of the eye.

Researchers began studying medical cannabis for the treatment of glaucoma in the 1970s after noting that the drug’s use lowered intraocular pressure — or IOP — which causes nerve damage that can lead to vision loss or blindness. While the National Eye Institute and other organizations supported early research in the late 1970s, they discontinued these studies and moved onto prescription and laser treatment options, even as medical cannabis research advanced.

Despite its potential benefits, the ophthalmology industry remains staunchly opposed to the use of medical cannabis to treat eye disorders. The American Glaucoma Society issued a statement in 2009 recommending against medical cannabis treatment for glaucoma, saying that the drug produces only short-term results and the adverse side-effects may not be worth it. These sentiments have been mirrored in more recent publications and advisories as well.

AXIM Biotech, a company specializing in cannabinoid research and development, is committed to developing cannabinoid-based therapies for glaucoma and dry eye. These research efforts are led by Dr. Robert Ritch, MD, who is a noted glaucoma specialist. This potentially groundbreaking research was featured recently in renowned medical outlet, Ophthalmology Innovation Summit.

Dr. Ritch became interested in the effects of medical cannabis on glaucoma when a 73 year old patient with IOPs usually in the 20s came into the office with a reading of 13mm Hg. The individual admitted to smoking marijuana the night prior, but not in the morning, which seemed to contradict popular beliefs that the IOP-lowering effects of medical cannabis only lasted a few hours at best — this appeared to last through the next day.

Dr. Ritch’s research centers on the theory that multiple cannabinoids act together in different ways that could affect IOP and other metrics. For example, there could be a drop or other formulation that not only lowers IOP but also provides neuroprotection, providing a double mechanism of action — one in the front of the eye and one in back of the eye. Devices like the Triggerfish — a contact lens sensor — could then be used to collect efficacy data over time.

Please follow the link to read the full article: http://analysis.secfilings.com/articles/160-axim-biotech-new-clinical-program-featured-in-national-ophthalmology-publication-reignites-hope-for-glaucoma-cannabis-therapy

About SECFilings.com

Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.